MAPT and Alzheimer disease: In addition, the neurodegenerative markers T-tau, 181p-tau, and Aβ1–42 successfully differentiate between AD and iNPH and therefore may be candidate biomarkers for determining the prognosis and shunt response of patients with iNPH (Jingami et al., 2015a).